ADMA Biologics
ADMA
368 hedge funds and large institutions have $3.84B invested in ADMA Biologics in 2025 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 152 increasing their positions, 106 reducing their positions, and 55 closing their positions.
70% more call options, than puts
Call options by funds: $53M | Put options by funds: $31.2M
45% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 55
43% more repeat investments, than reductions
Existing positions increased: 152 | Existing positions reduced: 106
6% more funds holding
Funds holding: 346 → 368 (+22)
1.61% more ownership
Funds ownership: 86.78% → 88.39% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less capital invested
Capital invested by funds: $4.07B → $3.84B (-$232M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$92.2M |
| 2 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$36.7M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$34M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$29.6M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$60.2M |
| 2 |
Two Sigma Advisers
New York
|
-$31.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$30.4M |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$22M |
| 5 |
Two Sigma Investments
New York
|
-$21.5M |
ADMA Hedge Fund Activity: Q2 2025 in Review
368 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2025, worth a combined $3.84B — down 5.7% from $4.07B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new ADMA positions and 55 closed out — a net gain of 25 holders — while 152 added to existing stakes and 106 trimmed.
The largest buyer was Vanguard Group, adding an estimated $92.2M. The largest seller was Morgan Stanley, cutting an estimated $60.2M.
- 368 institutional investors held ADMA Biologics (ADMA) as of Q2 2025, up from 346 in Q1 2025.
- Funds reported $3.84B of ADMA Biologics stock for Q2 2025, down 5.7% quarter-over-quarter.
- 80 funds opened new ADMA Biologics positions in Q2 2025 and 55 closed out, a net change of +25 holders.
- The largest ADMA Biologics buyer in Q2 2025 was Vanguard Group, an estimated $92.2M added.
- The largest ADMA Biologics seller in Q2 2025 was Morgan Stanley, an estimated $60.2M sold.
Based on aggregated 13F filings for Q2 2025.